▶ 調査レポート

世界の心臓補綴装置市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Cardiac Prosthetic Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cardiac Prosthetic Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)「世界の心臓補綴装置市場2022年-2027年:成長・動向・新型コロナの影響・市場予測」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2203A111
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、120ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本市場調査レポートでは、世界の心臓補綴装置市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別(心臓弁、ペースメーカー)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の心臓補綴装置市場規模:製品別(心臓弁、ペースメーカー)
・世界の心臓補綴装置市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Abbott Laboratories、LivaNova PLC、Medtronic plc、…)
・市場機会・将来傾向

The Cardiac Prosthetic Devices Market studied was anticipated to grow with a CAGR of nearly 9.2% during the forecast period. The major factors attributing to the growth of the market are the rise in the prevalence of multiple cardiovascular indications, atrial fibrillation, cardiac valve failure, and stroke lead to high mortality rates and stroke among geriatrics. For instance, according to Global Health And Wellness Report – 2018, more than 40% of the adult population in United States have been diagnosed with a cardiovascular condition in 2018 which will positively help the market growth, necessitating the high requirement of heart valve replacement devices and pacemakers to enhance cardiac functioning which likely to drive the market growth throughout the forecast period.

Key Market Trends

Mechanical Valves are Expected to Hold the Largest Market Share in the Cardiac Prosthetic Devices Market.

  • The Mechanical Valves attribute the largest share in the market owing to their lifetime solution for the patient due to their mechanical strength and flexibility of durable raw polymeric materials used in their manufacturing process. Furthermore, the increased preference by the physicians and patients due to their reduced risk of clinical problems compared to other valves and the lesser requirement for repetitive surgeries with these valves also contribute to the rise in the adoption of these systems fueling the growth of the market.
  • On the other hand, transcatheter heart valves are anticipated to witness significant growth over the forecast period owing to their minimal invasiveness nature compared to surgical procedures. The replacement devices are the highly effective and potent alternative for patients at greater risk from the standard valve replacement surgery, extensive congenital malformation, calcification, or infection contributing to the market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global cardiac prosthetic devices market throughout the forecast period. The dominance is due to the rising prevalence of cardiovascular disorders such as arrhythmia, heart failures, ischemic heart disease, dyspnea and heart valve imbalance owing to their unhealthy lifestyle in the United States which generates higher demand for the replacement devices. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases resulted in a higher demand for better treatment technologies driving the market in the United States. Also, increasing awareness programs by healthcare associations such as The American Heart Association and manufacturers by promoting positive health and the advantages of technologically advanced prosthetics along with the availability of advanced healthcare infrastructure in the region contributes for its outstanding share in the global market revenue.

Competitive Landscape

The Cardiac Prosthetic Devices market is moderately competitive and consists of several major players. Most of the key players currently dominating the market are focusing on technological advancements to address the unmet needs of cardiac diseases with the enhanced safety of the cardiac prosthetic devices resulting in demand for the market. While others are launching new products and actively making acquisitions with the other companies to consolidate their market positions across the globe and. For instance, in January 2017, Abbott acquired St. Jude Medical, added Trifecta Valve with Glide Technology in the U.S. that utilizes advanced technology, which is further such as expected to foster the industry growth propelling the market revenue. Some of the companies which are currently dominating the market are Abbott Laboratories, LivaNova PLC, Medtronic plc, Boston Scientific Corporation, and Edwards Lifesciences Corporation

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Popuation and Rise in Global Healthcare Expenditure along with Growth in Disposable Income
4.2.2 Rise in Global Prevalence of Cardiac Failures, Strokes and Availability of Technologically Advanced Products
4.3 Market Restraints
4.3.1 Stringent FDA Regulations for Class II Category Devices Which Should Comply to the Performance Standards
4.3.2 High Cost of Implantation and Risk of Repetitive Surgeries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Product
5.1.1 Heart Valves
5.1.1.1 Tissue Valve
5.1.1.2 Transcatheter Valve
5.1.1.3 Mechanical Valve
5.1.2 Pacemaker
5.1.2.1 Implantable Pacemaker
5.1.2.2 External Pacemaker
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 LivaNova PLC
6.1.3 Medtronic plc
6.1.4 Boston Scientific Corporation
6.1.5 Edwards Lifesciences Corporation
6.1.6 Colibri Heart Valve
6.1.7 Meril Life Sciences Pvt Ltd
6.1.8 Biotronik
6.1.9 Lepu Medical Technology Co Ltd
6.1.10 Siemens AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS